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Background
Although in bipolar patients the main therapeutic indica-
tion of olanzapine (OLA) is the management of acute
mania, several observations suggest that this agent may
exert antidepressant as well as antimanic effects. However,
in our knowledge, there are no preclinical studies support-
ing this hypothesis. Thus, the main goal of the present
work was to evaluate the putative antidepressant effect of
OLA (0.02–0.1 or 0.5 mg/kg/day), in comparison to
amitriptyline (AMI) (5 mg/kg/day), haloperidol (HAL)
(0.2 mg/kg/day) and sodium valproate (VPA) (5.0 or 30
mg/kg/day), in rats exposed to a protocol of chronic mild
stress (CMS). The second aim of this project was to assess
the efficacy of OLA, AMI, HAL and VPA in reverting the
cognitive impairment produced by the anhedonic state.
Both control and anhedonic rats will be subjected to two
short-memory paradigms, the place recognition test and
the object discrimination test, in order to evaluate the
effects of the examined drugs on visuo- spatial memory.
Materials and methods
One of the following stressors was administered daily (in
random order) over a period of 3–4 weeks: crowding, by
placing 8 animals in standard individual cages for 24
hours, food deprivation for 24 hours, 45° cage tilt for 5
hours, shaker stress (horizontal shakes at high speed) for
10 minutes, soiled cage (200 ml water in sawdust bed-
ding), intermittent overnight illumination (light on and
off every 3 hours), light on overnight (24 hours), tail
pinch for 2 minutes, swimming in cold water (16°C) for
5 minutes. Sucrose consumption tests were performed 7,
14, 21 and 28 days after the beginning of the CMS proce-
dure. In drug experiments, stress was continued through-
out the treatment period (28 days) and weekly sucrose
preference tests were carried out 24 hours after the last
drug administration. Sucrose consumption tests were also
performed 2, 5, 7, 14, 21 and 28 days after the end of the
CMS administration in order to achieve detailed informa-
tion about recovery from anhedonia. The spatial memory
was evaluated by testing the ability of the rats to discrimi-
nate a familiar versus a novel environment, while the vis-
ual memory was assessed by testing the ability of the rast
to discriminate familiar versus novel objects.
Results
The repeated administration of low doses of OLA, in a
rodent model of depression, has protective effects against
the anhedonia induced by the CMS protocol. Compared
to HAL and VPA, OLA shows a greater antidepressant
activity and is as effective as AMI in preventing the anhe-
donic state. The effects of OLA and AMI, however, have a
different time-course. A full reversion of the anhedonia by
AMI appears after a latency of four weeks, whereas the
effect of OLA is evident already one week after the begin-
ning of the chronic treatment. The administration of CMS
protocol causes a memory impairment both in the place
recognition and object discrimination test. In naive rats
VPA, OLA 0.02 or 0.1 mg/kg/day and HAL cause no
detectable modification of visual short-term memory in
comparison to saline group, although they do not revert
the impairment of cognitive performance of anhedonic
rats. VPA 5 mg/kg/day or OLA 0.02 mg/kg/day do not
modify spatial short-term memory in naive rats while the
lowest dose of OLA reverts the stress-induced cognitive
impairment of anhedonic rats.
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The chronic administration of low-dose OLA causes rapid
and sustained antidepressant-like effects, whereas all
other antimanic treatments show loss of efficacy at three
weeks. In addition, the chronic administration of low-
dose OLA seems to be more effective than administration
of VPA or HAL to prevent the CMS-related damage of vis-
ual and spatial short-term memories. Taken toghether,
these observations support the hypothesis that OLA has a
broader pharmacotherapeutic profile than solely as an
antipsychotic or antimanic agent and that it has the
potential to lead to substantial cognitive benefits in
depressed patients.Page 2 of 2
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